Targeting MRNA-coding Genes in Prostate Cancer Using CRISPR/Cas9 Technology with a Special Focus on Androgen Receptor Signaling

Overview

Journal Cell Commun Signal

Publisher Biomed Central

Specialties Biochemistry
Cell Biology

Date 2024 Oct 18

PMID 39420406

Authors

Mobina Tabibian

Fahimeh Salasar Moghaddam

Elahe Motevaseli

Soudeh Ghafouri-Fard

Affiliations

Soon will be listed here.

Abstract

Background: Prostate cancer is among prevalent cancers in men. Numerous strategies have been proposed to intervene with the important prostate cancer-related signaling pathways. Among the most promising strategies is CRISPR/Cas9 strategy. This strategy has been used to modify expression of a number of genes in prostate cancer cells.

Aims: This review summarizes the most recent progresses in the application of CRISPR/Cas9 strategy in modification of prostate cancer-related phenotypes with an especial focus on pathways related to androgen receptor signaling.

Conclusion: CRISPR/Cas9 technology has successfully targeted several genes in the prostate cancer cells. Moreover, the efficiency of this technique in reducing tumor burden has been tested in animal models of prostate cancer. Most of targeted genes have been related with the androgen receptor signaling. Targeted modulation of these genes have affected growth of castration-resistant prostate cancer. PI3K/AKT/mTOR signaling and immune response-related genes have been other targets that have been successfully modulated by CRISPR/Cas9 technology in prostate cancer. Based on the rapid translation of this technology into the clinical application, it is anticipated that novel treatments based on this technique change the outcome of this malignancy in future.

References

Li S, Fong K, Gritsina G, Zhang A, Zhao J, Kim J . Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2019; 79(10):2580-2592. PMC: 6522281. DOI: 10.1158/0008-5472.CAN-18-2812. View

Lau V, Davie J . The discovery and development of the CRISPR system in applications in genome manipulation. Biochem Cell Biol. 2017; 95(2):203-210. DOI: 10.1139/bcb-2016-0159. View

Li G, Kanagasabai T, Lu W, Zou M, Zhang S, Celada S . KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis. Cancer Res. 2020; 80(21):4633-4643. PMC: 8034842. DOI: 10.1158/0008-5472.CAN-20-0505. View

Zhen S, Takahashi Y, Narita S, Yang Y, Li X . Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome. Oncotarget. 2016; 8(6):9375-9387. PMC: 5354738. DOI: 10.18632/oncotarget.14072. View

Amitai G, Sorek R . CRISPR-Cas adaptation: insights into the mechanism of action. Nat Rev Microbiol. 2016; 14(2):67-76. DOI: 10.1038/nrmicro.2015.14. View

Wei C, Wang F, Liu W, Zhao W, Yang Y, Li K . CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells. Mol Med Rep. 2017; 17(2):2901-2906. PMC: 5783506. DOI: 10.3892/mmr.2017.8257. View

Anelli V, Villefranc J, Chhangawala S, Martinez-McFaline R, Riva E, Nguyen A . Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression. Elife. 2017; 6. PMC: 5389860. DOI: 10.7554/eLife.20728. View

Shi Q, Zhu Y, Ma J, Chang K, Ding D, Bai Y . Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly. Mol Cancer. 2019; 18(1):170. PMC: 6878651. DOI: 10.1186/s12943-019-1096-x. View

Park J, Kim J, Jeon Y, Lee M, Choi J, Song B . Deletion of NKX3.1 via CRISPR/Cas9 Induces Prostatic Intraepithelial Neoplasia in C57BL/6 Mice. Technol Cancer Res Treat. 2020; 19:1533033820964425. PMC: 7586030. DOI: 10.1177/1533033820964425. View

10.

Jin X, Qing S, Li Q, Zhuang H, Shen L, Li J . Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis. Nucleic Acids Res. 2021; 49(12):6788-6803. PMC: 8266658. DOI: 10.1093/nar/gkab489. View

11.

Rushworth L, Harle V, Repiscak P, Clark W, Shaw R, Hall H . In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer. Life Sci Alliance. 2020; 3(12). PMC: 7556750. DOI: 10.26508/lsa.202000770. View

12.

Laplante M, Sabatini D . mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-93. PMC: 3331679. DOI: 10.1016/j.cell.2012.03.017. View

13.

Rafiei S, Gui B, Wu J, Liu X, Kibel A, Jia L . Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer. Mol Cancer Res. 2018; 17(1):263-276. PMC: 6318022. DOI: 10.1158/1541-7786.MCR-18-0412. View

14.

Ho T, Huang J, Zhou N, Zhang Z, Koirala P, Zhou X . Regulation of PCGEM1 by p54/nrb in prostate cancer. Sci Rep. 2016; 6:34529. PMC: 5041109. DOI: 10.1038/srep34529. View

15.

Mukhopadhyay C, Yang C, Xu L, Liu D, Wang Y, Huang D . G3BP1 inhibits Cul3 to amplify AR signaling and promote prostate cancer. Nat Commun. 2021; 12(1):6662. PMC: 8602290. DOI: 10.1038/s41467-021-27024-x. View

16.

Li N, Xue W, Yuan H, Dong B, Ding Y, Liu Y . AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis. J Clin Invest. 2017; 127(4):1284-1302. PMC: 5373871. DOI: 10.1172/JCI91144. View

17.

Caggia S, Chunduri H, Millena A, Perkins J, Venugopal S, Vo B . Novel role of Giα2 in cell migration: Downstream of PI3-kinase-AKT and Rac1 in prostate cancer cells. J Cell Physiol. 2018; 234(1):802-815. PMC: 6202161. DOI: 10.1002/jcp.26894. View

18.

Cai H, Zhang B, Ahrenfeldt J, Joseph J, Riedel M, Gao Z . CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression. Nat Commun. 2024; 15(1):2088. PMC: 10920892. DOI: 10.1038/s41467-024-46370-0. View

19.

Yu Y, Papukashvili D, Ren R, Rcheulishvili N, Feng S, Bai W . siRNA-based approaches for castration-resistant prostate cancer therapy targeting the androgen receptor signaling pathway. Future Oncol. 2023; 19(30):2055-2073. DOI: 10.2217/fon-2023-0227. View

20.

Wenta T, Schmidt A, Zhang Q, Devarajan R, Singh P, Yang X . Disassembly of α6β4-mediated hemidesmosomal adhesions promotes tumorigenesis in PTEN-negative prostate cancer by targeting plectin to focal adhesions. Oncogene. 2022; 41(30):3804-3820. PMC: 9307480. DOI: 10.1038/s41388-022-02389-5. View